Debate: Idiopathic short stature should be treated with growth hormone
Version of Record online: 15 MAY 2012
© 2012 The Authors. Journal of Paediatrics and Child Health © 2012 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
Journal of Paediatrics and Child Health
Volume 49, Issue 3, pages 165–169, March 2013
How to Cite
Ambler, G. R., Fairchild, J. and Wilkinson, D. J. (2013), Debate: Idiopathic short stature should be treated with growth hormone. Journal of Paediatrics and Child Health, 49: 165–169. doi: 10.1111/j.1440-1754.2012.02465.x
- Issue online: 10 MAR 2013
- Version of Record online: 15 MAY 2012
- Accepted for publication 6 February 2012.
- body height;
- clinical ethics;
- human growth hormone/therapeutic use;
- short stature
In this paper we outline the case for and against the treatment of idiopathic short stature with growth hormone. Drs Ambler and Fairchild argue that many of those with ‘idiopathic’ short stature are not ‘short, normal children’ and will ultimately receive molecular diagnoses. They also argue that there is a subset of children who suffer negative psychosocial consequences of their stature for whom growth hormone therapy is effective. Growth hormone has a very good safety record and is likely to be as cost-effective in idiopathic short-stature as in some other conditions that are currently funded. Dr Wilkinson counters that short stature is not associated with physical or psychological illness, and that there is no evidence that growth hormone improves psychological or physical wellbeing. Moreover, growth hormone for idiopathic short stature represents a form of enhancement rather than treatment, and is not a fair use of resources. Socially mediated disadvantage should be treated by attention to prejudice and not by hormone treatment.